FLT1 and cancer: Thus, DIG-MSK was a strong inhibitor of VEGF pathway; but, contrasting with other anti-angiogenic drugs, DIG-MSK showed a dual effect inhibiting both VEGFA expression in cancer cells and VEGFR1 and VEGFR2 expression in ECs.